gebhart/patrepeval huggingface dataset:
Regulation of interleukin 6 in multiple myeloma and bone marrow stromal cells. (1995)

We and others have shown that some freshly isolated multiple myeloma (MM) cells and derived cell lines express interleukin 6 (IL-6) receptors and proliferate in vitro in response to IL-6; a subset of MM cells also expresses IL-6 mRNA, is intracytoplasmic IL-6 positive and secretes IL-6. We have shown that MM cells express the cell surface adhesion molecules CD29/CDw49d(VLA-4), CD18/CD11a(LFA-1) and CD44, and may localize to marrow via specific adherence to both extracellular matrix proteins and to bone marrow stromal cells (BMSCs). MM cell adhesion triggers IL-6 secretion by normal and MM BMSCs and related IL-6-mediated tumor cell growth. Our attempts to block MM cell adhesion to BMSC-induced IL-6 secretion by using antibodies to CD29/CDw49d, CD18/11a, and/or CD44 demonstrated minimal effects, suggesting that another ligand-receptor interaction triggers IL-6 secretion when MM cells and BMSCs are juxtaposed. Both MM cells and BMSCs express CD40. Triggering of MM cells and BMSCs via CD40 upregulates IL-6 secretion in both MM cells and MM-derived cell lines, as well as BMSCs and BMSC lines, suggesting the possibility of both autocrine and paracrine MM cell growth triggered via CD40. Finally, experiments using the LP 101 BMSC line transiently transfected with IL-6 promoter fragments linked to chloramphenicol acetyltransferase reporter gene demonstrate that adhesion of MM cells induces IL-6 gene transcription in BMSCs, which is conferred via the NF-kappa B binding motif.(ABSTRACT TRUNCATED AT 250 WORDS)
New multiple‐herbicide crop resistance and formulation technology to augment the utility of glyphosate (2007)

Glyphosate has performed long and well, but now some weed communities are shifting to populations that survive glyphosate, and growers need new weed management technologies to augment glyphosate performance in glyphosate-resistant crops. Unfortunately, most companies are not developing any new selective herbicides with new modes of action to fill this need. Fortunately, companies are developing new herbicide-resistant crop technologies to combine with glyphosate resistance and expand the utility of existing herbicides. One of the first multiple-herbicide-resistant crops will have a molecular stack of a new metabolically based glyphosate resistance mechanism with an active-site-based resistance to a broad spectrum of ALS-inhibiting herbicides. Additionally, new formulation technology called homogeneous blends will be used in conjunction with glyphosate and ALS-resistant crops. This formulation technology satisfies governmental regulations, so that new herbicide mixture offerings with diverse modes of action can be commercialized more rapidly and less expensively. Together, homogeneous blends and multiple-herbicide-resistant crops can offer growers a wider choice of herbicide mixtures at rates and ratios to augment glyphosate and satisfy changing weed management needs.
The vertebrate peptide antibiotics dermaseptins have overlapping structural features but target specific microorganisms. (1994)

The physiological significance of the occurrence of sequence similar antimicrobial peptides in frog skin, as the bombinins in Bombina, the magainins in Xenopus, and the dermaseptins in Phyllomedusa, is a major unanswered question. Dermaseptins s1, s2, s3, s4, and s5, a family of cationic (lysine-rich), amphipathic antifungal peptides of 28-34 residues were thus synthesized, purified to homogeneity, and evaluated for their growth-inhibition activity in vitro against various pathogenic microorganisms. Although all five of these peptides shared a similar spectrum of lytic activity against the filamentous fungi that are responsible for opportunistic lethal infections that follow the immunodeficiency syndrome or the use of immunosuppressive agents, they exhibited marked differences in their potencies to arrest the growth of Gram-positive and Gram-negative pathogenic bacteria and yeasts. Likewise, whereas dermaseptins s1 and s5 were devoid of hemolytic activity, dermaseptin s4 caused lysis of erythrocytes at micromolar concentrations. The dermaseptins exhibited dramatic synergy of action upon combination, resulting in some cases in a 100-fold increase in antibiotic activity of the mixture over the activity of the peptides separately. Shortening the peptide chain of dermaseptin s3 to dermaseptin s3-(1-16)-NH2 did not affect the antimicrobial potency of the peptide. Further reduction of the chain length yielded peptide derivatives gradually showing reduced activity. Surprisingly, however, analogs of dermaseptin s3 as shorter as 10-12 residues in length remained fully active against Enterococcus faecalis, Cryptococcus neoformans, and against Aeromonas caviae, the causal agent of red-leg disease in amphibians. Overall, these results suggest that, despite 40% sequence similarities, the dermaseptins have distinct spectra of anti-microbial activity and may act in concert to circumvent host invasion by providing frogs with a better shielding against a broad array of microorganisms. They also demonstrate the potential usefulness of short analogs of these peptides as potential candidates for biorational design of germicides.
PML and rheumatology: The contribution of disease and drugs (2011)

Progressive multifocal leukoencephalopathy (PML), a rare, typically fatal, opportunistic infection caused by the JC virus, is becoming relevant to physicians in multiple specialties, including those who prescribe biologic agents for the treatment of autoimmune disorders. Reports of PML have led to US Food and Drug Administration alerts and warning letters regarding four immunosuppressive agents in recent years (natalizumab, rituximab, efalizumab, and mycophenolate mofetil). Consequently, informed clinical decision-making requires understanding the risk of PML associated with these therapies. An estimate of the relative frequency of PML associated with specific rheumatic conditions has been generated. Systemic lupus erythematosus appears to be associated with susceptibility to PML that cannot be fully explained by the intensity of immunosuppressive therapy. Further, the use of rituximab in patients with rheumatic disease has raised concerns. However, definitive attribution of cause is precluded by the limitations of the currently available data. All patients with rheumatic disease, regardless of the intensity of their current immunosuppressive therapy, should be considered potentially at risk of PML. With an evolving understanding of a greater clinical heterogeneity of PML, advances in diagnostic methods, and significant implications for therapy, PML should be considered in the differential diagnosis of neurologic manifestations of rheumatic diseases.
Cloning and characterization of theYarrowia lipolytica squalene synthase (SQS1) gene and functional complementation of theSaccharomyces cerevisiae erg9 mutation (2000)

The squalene synthase (SQS) gene encodes a key regulatory enzyme, farnesyl-diphosphate farnesyltransferase (EC 2.5.1.21), in sterol biosynthesis. The SQS1 gene was isolated from a subgenomic library of the industrially important yeast Yarrowia lipolytica, using PCR-generated probes. Probes were based on conserved regions of homologues from different organisms. The complete nucleotide sequence of the coding region and the corresponding amino acid sequence were determined. The sequences showed extensive homologies with squalene synthase genes and enzymes from a number of other organisms and extreme amino acid conservation within the binding and catalytic domains. Direct cloning of a 4.3 kb genomic Y. lipolytica fragment, also comprising its own promoter and terminator sequences, into autonomously replicating plasmid YEp352 and subsequent transformation of a Saccharomyces cerevisiae mutant strain with relevant erg9: ura3-1 markers, resulted in functional complementation of these deficiencies, although Northern blot analyses did not reveal a unique full-length messenger. The availability of the Y. lipolytica SQS1 gene (GenBank Accession No. AF092497) offers prospects for metabolic engineering of the isoprenoid and sterol biosynthetic pathways.
Fluorescence in situ hybridization for direct visualization of Gram-negative anaerobes in subgingival plaque samples (1993)

Fluorescent oligonucleotide probes complementary to variable regions of Porphyromonas gingivalis and Bacteroides forsythus 16S ribosomal RNA were used to identify these organisms in smears of formaldehyde-fixed subgingival plaque samples from patients suffering from periodontitis. Fluorescence in situ hybridization represents a useful method for assessing the microbial ecology of the periodontal flora.
Asymmetric synthesis of 3-butylphthalide using isomannide and isosorbide as chiral auxiliaries (2007)

为(S) 和(R)-3-n-butylphthalide (NBP ) 的不对称的综合体的一条新途径被介绍。到 10 或 11 从导出 isomannide 或导出 isosorbide 的 chiral 产生了的芳香的醛的 dibutylzinic 的 diastereoselective 增加在高光的收益的辅助负担得起的 S-NBP 或 R-NBP。
Prevalence of Agonistic Autoantibodies Against the Angiotensin II Type 1 Receptor and Soluble fms-Like Tyrosine Kinase 1 in a Gestational Age–Matched Case Study (2008)

We showed earlier that activating autoantibodies against the angiotensin II type 1 (AT(1)) receptor (AT1-AA) circulate in preeclamptic women. They may be involved in the pathogenesis of preeclampsia. Protein alignment suggests that the binding site for AT1-AAs is highly homologous to the capsid protein VP2 of parvovirus B19. We performed a prospective, nested, case-control study of 30 gestational age-matched women with preeclampsia and 30 normotensive pregnant women. We measured AT1-AA, soluble fms-like tyrosine kinase 1 (sFlt-1), and serum immunoglobulin G against parvovirus B19 proteins. AT1-AAs were present in 70% of preeclamptic patients and absent in 80% of controls. Prediction by AT1-AA was improved in late-onset preeclampsia. The discrimination for sFlt-1 was 96%. We did not find an interaction between sFlt-1 and AT1-AA. A human monoclonal immunoglobulin G antibody against parvovirus B19 VP2-protein showed a positive reaction in the AT1-AA bioassay, which could be blocked by an AT(1) receptor blocker, as well as by the epitope amino acid sequence. Immunoglobulin G against parvovirus B19 proteins was similarly distributed between preeclamptic patients and controls and had no significant importance. We detected significantly more AT1-AA in women with an immune response corresponding with parvovirus B19 infection corresponding with a distant viral infection associated with virus elimination. We concluded that AT1-AAs were common in patients with preeclampsia in a prospective case-control study, although sFlt-1 was a superior biomarker. AT1-AA may represent a better marker for late disease, whereas sFlt1 is a better marker for early onset disease.
Triple-negative breast cancer: bridging the gap from cancer genomics to predictive biomarkers (2014)

Triple-negative breast cancer (TNBC) represents a challenge clinically due to a lack of response to hormonal and HER2-targeted agents coupled with an aggressive disease course. As the biology of this breast cancer subtype is better understood, it is clear that TNBC is a heterogeneous disease and one targeted therapy is unlikely to be active in all patients. Biomarkers predictive of response to treatment are thus of great importance in TNBC. This review outlines studies evaluating biomarkers predictive of response to neoadjuvant chemotherapy and to targeted therapies in the advanced setting. The development of validated biomarkers in conjunction with novel targeted therapies represents an opportunity to improve patient outcomes in TNBC.
The Microcirculation and Inflammation: Site of Action for Glucocorticoids (2000)

The glucocorticoid hormones and their synthetic derivatives are potent suppressors of inflammatory and allergic pathologies. Their widespread efficacy is the result of multiple modes of action occurring predominantly at the level of the microcirculation. Indeed the glucocorticoids interfere with the function of all of the cellular components of the microcirculation associated with an inflammatory response. These agents inhibit vasodilatation of the arteriolar and capillary beds. therefore preventing the increase in blood flow that characterizes the initial stages of the inflammatory response. They also prevent increases in vascular permeability in the capillary and post-capillary venule, thereby reducing exudate formation. Finally, the glucocorticoids potently suppress leukocyte emigration across post-capillary venules. However, this promiscuity of the glucocorticoids to act at multiple sites also endows this class of (drugs with major side effects associated with chronic treatment. We propose that one way to progress forward is to understand better the effects of glucocorticoids within the microcirculation. This may aid identification of specific molecular sites of action and therefore the development of novel glucocorticoid molecules with fewer side effects.
A human major histocompatibility complex class I gene that encodes a protein with a shortened cytoplasmic segment. (1987)

We have cloned genomic DNA encoding a non-HLA-A, -B, -C class I gene located within a HindIII-generated restriction fragment of 6.0 kilobase pairs. This gene, designated HLA-6.0, is as homologous to HLA-A and HLA-B as they are to each other. The HLA class I protein encoded by HLA-6.0 is similar in organization to the HLA-A-, -B-, and -C-encoded proteins except that an in-frame termination codon prevents translation of a majority of the cytoplasmic region of the HLA-6.0 polypeptide. Moreover, the promoter region of HLA-6.0 resembles the promoter region of a Qa region gene. These structural features of HLA-6.0 suggest that this non-HLA-A, -B, -C gene is a structural homolog of a murine Qa region class I gene.
High-Density Lipoprotein Restores Endothelial Function in Hypercholesterolemic Men (2002)

In hypercholesterolemic patients, intravenous rHDL infusion rapidly normalizes endothelium-dependent vasodilation by increasing NO bioavailability. This may in part explain the protective effect of HDL from coronary heart disease and illustrates the potential therapeutic benefit of increasing HDL in patients at risk from atherosclerosis.
Determination of the levels of urokinase and its receptor in human colon carcinoma cell lines. (1988)

At present, there is a lack of availability of differentiation markers for colon carcinoma. This may, in part, be a consequence of the diversified function of the normal human colon. This study addresses the possibility that the expression of urokinase and its receptor is inversely related to differentiation in colon carcinoma. Six colon carcinoma cell lines including three well-differentiated (CBS, GEO, FET) and three poorly differentiated ones (HCT116, HCT116b, RKO) were screened for urokinase receptor display and secretion of the plasminogen activator. A radioreceptor assay was used to determine receptor levels. Binding of radioactive urokinase to colon cells was saturable, specific, and time dependent. Cell-bound 125I-labeled protease was unaffected by the presence of epidermal growth factor, low-molecular-weight urokinase, plasminogen, or transferrin. Time course studies revealed that maximum amounts of radioactive tracer were bound in a 30-min period with no change occurring over the course of a 90-min incubation. Scatchard analysis of ligand binding indicated that the well-and poorly differentiated cells could be separated on the basis of receptor display; the aggressive RKO, HCT116, and HCT116b expressed in excess of 10(5) sites per cell, while the more indolent CBS, GEO, and FET possessed less than 1.5 X 10(4) receptors per cell. The colon carcinoma cells were also analyzed for urokinase in the conditioned medium. Low levels of the plasminogen activator (0.8 to 1.3 ng/ml/10(6) cells/72 h) were associated with the more "mature" cells. This was in contrast to the elevated levels of the protease (3.9 to 11.4 ng/ml/10(6) cells/72 h) present in the medium derived from the more aggressive cells (HCT 116, HCT116b, RKO). Thus, secreted urokinase and/or the expression of cellular receptor for the plasminogen activator may provide useful measurements of the degree of undifferentiation of in vitro colon carcinoma.
List of contributors, Indexes (1975)

The purpose of this study was to evaluate the efficacy of intraarterial low-dose recombinant tissue plasminogen activator (rt-PA) in patients with acute or subacute thrombosis of the native arterial system or in an arterial artificial or venous by-pass graft. Twenty patients with 22 cases of thrombosis received intraarterial thrombolysis during the period 1.1.1995 to 31.12.1995. Ten patients (50%) achieved complete radiological thrombolysis, and in seven patients (35%) partial thrombolysis was achieved. Half of these patients required a subsequent PTA or an operation. There were only three patients (15%) where no lysis occurred. The results seemed very satisfactory and we conclude that thrombolysis should be considered as the first-choice treatment in this category of patients. The indications may be extended to patients with critical ischaemia with the introduction of the pulse-spray technique as the time to complete lysis is considerably shorter with this technique.
Development of a selenium-based flat-panel detector for real-time radiography and fluoroscopy (1998)

Flat-panel detector (FPD) is the driving force for realizing the next generation of x-ray systems. The purpose of this study was to develop a selenium-based FPD for both radiography and fluoroscopy. The detector uses amorphous selenium (a-Se) and a thin-film transistor (TFT) array. The simple construction of the a-Se layer permits real-time readout. The unique response characteristics of the FPD, which can be saturated over permitted x-ray doses, are provided by the TFT structure. Our prototype FPD was designed to acquire images at 30 frames per second (fps). A high modulation transfer factor was obtained: 0.63 at 2.0 Lp/mm. Sequential fluoroscopic images were acquired at up to 30 fps. The linear characteristics of the detector covered the commonly employed range of clinical exposure dose. Less than 1.5% image lag was measured at 30 fps.
Quantitative EEG Normative Databases: Validation and Clinical Correlation (2003)

The quantitative digital electroencephalogram (QEEG) was recorded from 19 scalp locations from 625 screened and evaluated normal individuals ranging in age from two months to 82 years. After editing to remove artifact, one-year to five-year groupings were selected to produce different average age groups. Estimates of gaussian distributions and logarithmic transforms of the digital EEG were used to establish approximate gaussian distributions when necessary for different
Identification of a developmentally regulated protein-tyrosine kinase by using anti-phosphotyrosine antibodies to screen a cDNA expression library. (1989)

To identify the protein-tyrosine kinases that are expressed during chicken embryonic development, a 10-day chicken embryo cDNA expression library was screened with anti-phosphotyrosine antibodies. Of the positive clones isolated, many encoded the same protein-tyrosine kinase, which we designate Cek1 (chicken embryo kinase 1). Its amino acid sequence suggests that the Cek1 protein is a transmembrane tyrosine kinase and presumably the receptor for an unknown ligand. Antibodies prepared to the cloned Cek1 kinase recognize, in immunoblotting experiments, two protein bands with apparent molecular weights of 100,000 and 110,000. The Cek1 protein was detected in many chicken embryonic tissues, but not in the corresponding adult tissues (with the exception of brain). The Cek1 kinase appears to be very closely related to two protein-tyrosine kinases whose partial sequences have been recently determined, human Flg and mouse Bek. Cloning using anti-phosphotyrosine antibodies has allowed us to detect, in addition to Cek1, several other protein-tyrosine kinases that are expressed during chicken embryonic development, some of which have not been previously identified.
Recent advances in CE‐MS coupling: Instrumentation, methodology, and applications (2016)

This review focuses on the latest development of microseparation electromigration methods in capillaries and microfluidic devices coupled with MS for detection and identification of important analytes. It is a continuation of the review article on the same topic by Kleparnik (Electrophoresis 2015, 36, 159-178). A wide selection of 161 relevant articles covers the literature published from June 2014 till May 2016. New improvements in the instrumentation and methodology of MS interfaced with capillary or microfluidic versions of zone electrophoresis, isotachophoresis, and isoelectric focusing are described in detail. The most frequently implemented MS ionization methods include electrospray ionization, matrix-assisted desorption/ionization and inductively coupled plasma ionization. Although the main attention is paid to the development of instrumentation and methodology, representative examples illustrate also applications in the proteomics, glycomics, metabolomics, biomarker research, forensics, pharmacology, food analysis, and single-cell analysis. The combinations of MS with capillary versions of electrochromatography, and micellar electrokinetic chromatography are not included.
Colloid Transport by Interfacial Forces (1989)

In a historical context the interface between two phases has played only a minor role in the physics of fluid dynamics. It is of course true that boundary conditions at interfaces, usually imposed as continuity of ve­ locity and stress, determine the field of a given flow; however, this is a more or less passive use of the interface that allows one to ignore the structure of the transition between two phases. When an interface has been assigned a more active role in flow processes, it generally has been assumed that one parameter, the interfacial (surface) tension, accounts for all mech­ anical phenomena (Young et al. 1 959, Levich & Krylov 1969). In these studies, kinematic effects of the interface were not considered, and the condition on the at interfaces was retained. The basic message of this article is that the interface is a region of small but finite thickness, and that dynamical processes occurring within this region lead not only to interfacial stresses but also to an apparent velocity that, on a macroscopic length scale, appears to be a violation of the no-slip condition. The existence of a slip at solid/fluid interfaces opens a class of flow problems not generally recognized by the fluid-dynamics community. Three previous articles in this series deal with flow caused by interactions between interfaces and external fields such as electrical potential, tem­ perature, and solute concentration. Melcher & Taylor ( 1969) and Levich & Krylov (1969) consider fluid/fluid interfaces where stresses produced at the interface by the external field dictate the flow. Saville ( 1977), on the other hand, discusses the action of an electric field on a charged solid/fluid interface and reviews the currently accepted model for electrophoretic